The primary purpose of the Organic Synthesis Facility (OSF) is to produce the highest quality synthetic molecules for Fox Chase Cancer Center (FCCC) investigators with peer-reviewed funding. Small organic molecules are used in many areas of research as specific reagents including those that are inhibitors of enzyme activity or protein binding. Some of these molecules have been used in the development of prodrugs against target proteins identified at FCCC. Analogs of natural substrates have been used to probe enzyme mechanism, to investigate protein function, or to test specific hypotheses. The molecules synthesized by the Facility are not purchasable from chemical companies, and custom synthesis from commercial enterprises is either not available or prohibitively expensive. Many of the molecules requested by investigators are novel and require the design of new synthetic routes and purification schemes. For molecules that have been previously synthesized, the Facility uses the published synthetic protocol. However, in more than 50% of these cases, the literature protocol either does not work as described or does not yield a sufficiently pure product and the Facility has to design new syntheses or purification schemes. During the last grant period (2000-2004), 32 different chemical syntheses were completed including eight novel compounds. The compounds synthesized were very diverse in structure and included a tamoxifen metabolite, a gadolinium complex, an antimycin analog, tritium-labeled estramustine, bromo naphthalenesulfonic acid and spin-labeled hydrazone. The synthesis of several novel inhibitors of retroviral integrases (AIDS Res. Hum. Retro. 20:135-144, 2004) exemplifies the quality science generated by the OSF. Seventeen articles, three co-authored by OSF staff, published in peer-reviewed journals from 2000-2004 used compounds that were synthesized in the OSF. The number of investigators with peer-reviewed funding using the OSF has increased from 25 in 2000 to 34 in 2003 (36%). Usage in 2003 was from all 11 Programs and 98% of use was by investigators with peer-reviewed funding. This usage includes syntheses, purification of reagents, chemical analysis, and consultation. Fifty-one (51) investigators with peer-reviewed funding utilized products and services from the OSF during the Core Grant period (2000-2004).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006927-46
Application #
7651439
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
46
Fiscal Year
2008
Total Cost
$246,919
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
073724262
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Reese, Jennifer Barsky; Smith, Katherine Clegg; Handorf, Elizabeth et al. (2018) A randomized pilot trial of a couple-based intervention addressing sexual concerns for breast cancer survivors. J Psychosoc Oncol :1-22
Shaikh, Talha; Handorf, Elizabeth A; Meyer, Joshua E et al. (2018) Mismatch Repair Deficiency Testing in Patients With Colorectal Cancer and Nonadherence to Testing Guidelines in Young Adults. JAMA Oncol 4:e173580
Roy, Anuradha (2018) Early Probe and Drug Discovery in Academia: A Minireview. High Throughput 7:
Auerbach, M V; Heckman, C J; Darlow, S (2018) To protect or not to protect: examining reasons for sun protection among young women at risk for skin cancer. J Behav Med 41:528-536
Diefenbach, Michael A; Benedict, Catherine; Miller, Suzanne M et al. (2018) Examining the impact of a multimedia intervention on treatment decision-making among newly diagnosed prostate cancer patients: results from a nationwide RCT. Transl Behav Med 8:876-886
Ross, Kayleigh C; Chin, Kevin F; Kim, Daehwan et al. (2018) Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib. Oncotarget 9:13324-13336
Shafi, Ayesha A; Schiewer, Matthew J; de Leeuw, Renée et al. (2018) Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. Eur Urol Oncol 1:325-337
Mazor, Anna M; Mateo, Alina M; Demora, Lyudmila et al. (2018) Breast conservation versus mastectomy in patients with T3 breast cancers (>?5 cm): an analysis of 37,268 patients from the National Cancer Database. Breast Cancer Res Treat :
Ingram, Justin P; Tursi, Sarah; Zhang, Ting et al. (2018) A Nonpyroptotic IFN-?-Triggered Cell Death Mechanism in Nonphagocytic Cells Promotes Salmonella Clearance In Vivo. J Immunol 200:3626-3634
Chang, Wen-Chi L; Jackson, Christina; Riel, Stacy et al. (2018) Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut 67:1290-1298

Showing the most recent 10 out of 1280 publications